Anthracycline-induced clinical heart failure in a cohort of 607 children: long-term follow-up study.

PURPOSE To determine the early and late cumulative incidence of anthracycline-induced clinical heart failure (A-CHF) after anthracycline therapy in childhood and to identify associated risk factors. PATIENTS AND METHODS The cumulative incidence of A-CHF and the risk factors of A-CHF were assessed in a cohort of 607 children who had been treated with anthracyclines between 1976 and 1996. For 96% of the cohort, we obtained the clinical status up to at least January 1997. The mean follow-up time was 6.3 years. RESULTS The cumulative incidence of A-CHF was 2.8%, after a mean follow-up time of 6.3 years and a mean cumulative dose of anthracyclines of 301 mg/m(2). A cumulative dose of anthracycline higher than 300 mg/m(2) was associated with an increased risk of A-CHF (relative risk, 11.8; 95% confidence interval, 1.6 to 59.5) compared with a cumulative dose lower than 300 mg/m(2). The estimated risk of A-CHF increased with time after the start of anthracycline chemotherapy to 2% after 2 years and 5% after 15 years. CONCLUSION Up to 5% of patients will develop A-CHF 15 years after treatment, and patients treated with a cumulative dose of anthracyclines higher than 300 mg/m(2) are at highest risk for A-CHF. This is thus a considerable and serious problem among these young patients. The findings reinforce the need for strategies for early detection of patients at risk for A-CHF and for the evaluation of other chemotherapeutic possibilities or cardioprotective agents in relation to the survival.

[1]  P. Steinherz,et al.  Cardiac failure and dysrhythmias 6-19 years after anthracycline therapy: a series of 15 patients. , 1995, Medical and pediatric oncology.

[2]  S. Sallan,et al.  Cardiac effects of anthracyclines used in the treatment of childhood acute lymphoblastic leukemia: a 10-year experience. , 1984, Seminars in oncology.

[3]  J. Krischer,et al.  Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  G. Levitt,et al.  Anthracycline dose in childhood acute lymphoblastic leukemia: issues of early survival versus late cardiotoxicity. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  S. Swain,et al.  Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  G. Levitt,et al.  Cardiac function in Wilms' tumor survivors. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  J. Mantle,et al.  Anthracycline-induced cardiomyopathy in children: a report of six cases. , 1984, Medical and pediatric oncology.

[8]  S. Colan,et al.  Monitoring for anthracycline cardiotoxicity. , 1994, Pediatrics.

[9]  A. Lincoff,et al.  Anthracycline-Induced Cardiotoxicity , 1996, Annals of Internal Medicine.

[10]  S. Colan,et al.  Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. , 1991, The New England journal of medicine.

[11]  D. V. Von Hoff,et al.  Risk factors for doxorubicin-induced congestive heart failure. , 1979, Annals of internal medicine.

[12]  S. Sternberg,et al.  The cardiotoxicity of adriamycin and daunomycin in children , 1976, Cancer.

[13]  S. Lipsitz,et al.  Relationship between cumulative anthracycline dose and late cardiotoxicity in childhood acute lymphoblastic leukemia. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  P. Steinherz,et al.  Cardiac toxicity 4 to 20 years after completing anthracycline therapy. , 1991, JAMA.

[15]  D. Cox Regression Models and Life-Tables , 1972 .

[16]  S. Sallan,et al.  Congestive heart failure due to adriamycin cardiotoxicity: Its natural history in children , 1981, Cancer.

[17]  J. Silber,et al.  Increased risk of cardiac dysfunction after anthracyclines in girls. , 1993, Medical and pediatric oncology.

[18]  F. Bu'Lock,et al.  Left ventricular diastolic function after anthracycline chemotherapy in childhood: relation with systolic function, symptoms, and pathophysiology. , 1995, British heart journal.

[19]  J. Pitha,et al.  A clinicopathologic analysis of adriamycin cardiotoxicity , 1973, Cancer.

[20]  A. Evans,et al.  Late effects of treatment for wilms' tumor. A report from the national wilms' tumor study group , 1991, Cancer.

[21]  E J Orav,et al.  Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. , 1995, The New England journal of medicine.